Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.

@article{Oda2013CharacterizationOT,
  title={Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.},
  author={Hitomi Oda and Akihiro Mori and Peter Lee and Kaori Saeki and Katsumi Ishioka and Toshiro Arai and Toshinori Sako},
  journal={Research in veterinary science},
  year={2013},
  volume={95 2},
  pages={381-8}
}
Glucagon-like peptide 1 (GLP-1) is a glucose-lowering, intestinal-derived factor with multiple physiological effects, making it attractive for diabetes therapy. However, the therapeutic potential of endogenous GLP-1 is limited, because of rapid inactivation by dipeptidyl peptidase-4. Recently, enhanced incretin preparations, such as liraglutide, have emerged, which are more resistant to degradation and longer lasting. Liraglutide is a long-acting acylated human GLP-1 receptor agonist, with a 97… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS